To the full analysis
Bioventus stock: growth
BVSBioventus reported $568.09M in revenue for fiscal 2025, down 0.9% on the prior year, up 12.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.7%
per year from 2013 to 2025, per share 6.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 12.1% | 8.4% | 7.7% |
| Revenue per share | 0.0% | 6.5% | 6.1% |
| Earnings | 6.7% | no data | no data |
| Earnings per share | −5.0% | no data | no data |
| Free cash flow | 6.9% | 20.1% | no data |
| Free cash flow per share | −4.6% | 17.9% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $232.38M | −$22.37M | −$3.61M |
| 2014 | $242.89M | −$12.9M | −$5.72M |
| 2015 | $253.65M | −$34.11M | $11.48M |
| 2016 | $274.5M | −$17.95M | $0 |
| 2017 | $292.06M | −$1.64M | $0 |
| 2018 | $319.18M | −$12.21M | $39.13M |
| 2019 | $340.14M | $6.85M | $0 |
| 2020 | $321.16M | $16.41M | $51.13M |
| 2021 | $430.9M | $19.38M | $2.1M |
| 2022 | $512.12M | −$158.7M | −$15.02M |
| 2023 | $512.35M | −$156.23M | $7.98M |
| 2024 | $573.28M | −$33.54M | $37.79M |
| 2025 | $568.09M | $22.73M | $71.41M |
Revenue by segment
How Bioventus Inc. makes its money and how that has shifted. Names are as the company reports them.
- U.S.88%
- International12%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| U.S. | $506.81M | $502.1M | 88.4% |
| International | $66.47M | $65.99M | 11.6% |
| Total revenue | $573.28M | $568.09M | 100% |
Revenue by region
Where Bioventus Inc. generates its revenue.
- United States88%
- Outside the US12%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| United States | $449.86M | $506.81M | $502.1M | 88.4% |
| Outside the US | $62.49M | $66.47M | $65.99M | 11.6% |
| Total revenue | $512.35M | $573.28M | $568.09M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.